Physician profile
Michael Joseph Scolieri
NPI 1679557011
$28,184.03
in general payments reported to CMS, 2019-2025
41 companies · $2,785 in 2025
The $2,785 reported for 2025 was more than what 86% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,149 · 2020: $1,250 · 2021: $984 · 2022: $993 · 2023: $1,948 · 2024: $13K · 2025: $2,785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $9,600 · Food and Beverage: $6,179 · Travel and Lodging: $2,025 · Education: $4.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $9,600.00 |
| Food and Beverage | $6,179.15 |
| Travel and Lodging | $2,024.50 |
| Education | $4.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $10,965.66 | 2023-2025 | Jelmyto |
| Astellas Pharma US INC | $7,224.15 | 2019-2024 | Myrbetriq, Veozah, Xtandi |
| Medtronic, INC. | $3,354.33 | 2021-2025 | Interstim, Altaviva |
| Medtronic USA, INC. | $1,030.84 | 2019-2020 | |
| Abbvie INC. | $986.08 | 2019-2025 | Botox |
| Allergan, INC. | $957.35 | 2019-2022 | |
| Axonics, INC. | $653.90 | 2021-2024 | Axonics, Bulkamid |
| Sumitomo Pharma America, INC. | $526.02 | 2023-2025 | Gemtesa, Orgovyx |
| Janssen Biotech, INC. | $296.73 | 2021-2025 | Erleada |
| Dendreon Pharmaceuticals LLC | $267.33 | 2020-2024 | Provenge |
| Urovant Sciences INC | $227.58 | 2021-2022 | |
| Neotract INC. | $204.89 | 2019-2020 | |
| Tolmar, INC. | $182.33 | 2023-2025 | Jatenzo, Eligard |
| Antares Pharma, INC. | $163.87 | 2022-2025 | Xyosted |
| Boston Scientific Corporation | $110.88 | 2019-2025 | Axonics |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Scolieri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.